Main Article Content

Dr. B. Prasath
Dr. Maduram Annamalai
Dr. Lavakumar Somu
Dr. Soundarya Priyadharsini
Dr. Reshma


Aspirin, Ibuprofen, Anti-cancer property, MCF 7 cell line, Breast cancer


Background: Breast cancer is a leading cause of morbidity and mortality among women worldwide. Insights employing MCF-7 cell lines for breast cancer research have continued unabatedly in the last five decades. The MCF-7 cell line has radically changed the trajectory of breast cancer research and helped to improve patient outcomes, despite the drawbacks of research on established cancer cell lines maintained in tissue culture and xenografts. NSAIDs, including Aspirin and Ibuprofen, have been associated with a reduced risk of breast cancer.

Objectives: The present study was undertaken as a pre-clinical cross-sectional study to evaluate and compare the anti-cancer properties of Aspirin and Ibuprofen in MCF 7 breast cancer cell lines.           

Methodology: 3-(4,5- dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, DAPI (4,6 Diamidino-2-phenylindole dihydrochloride) staining, Annexin assay and DNA fragmentation by Gel electrophoresis were employed in the study.

Results: IC50 values for Ibuprofen (28 μg/ml) were higher than Aspirin (21.18 μg/ml). No significant difference in the percentage of cancer cell death between Aspirin and Ibuprofen was noted. When combined, Aspirin and Ibuprofen showed significantly higher anti-cancer properties (IC50-14.93 μg/ml) on breast cancer cell lines compared to their standalone samples. Apoptosis level by annexin assay was increased at 15μg of Aspirin and Ibuprofen. DAPI staining also showed that a greater number of cancer cells were stained at 15μg of Aspirin and Ibuprofen. Fragmentation of the combination drugs of 10μg shows the highest apoptosis from control through DNA ladder Assay.                                                

Conclusion: Thus, Aspirin and Ibuprofen, exclusively and in combination, have been found to have anti-cancer properties against breast cancer cell lines through various laboratory methods.

Abstract 107 | pdf Downloads 65


1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al.Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast.2022 Dec;66:15–23.
2. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011 Aug;13(4):215.
3. Osborne CK, Hobbs K, Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat.1987;9(2):111–121.
4. Wong RSY. Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion. Adv Pharmacol Sci. 2019;2019:3418975.
5. Amaral MEA, Nery LR, Leite CE, de Azevedo Junior WF, Campos MM. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Invest New Drugs. 2018 Oct;36(5):782–796.
7. Julka P, Manoharan N, Nair O, Rath GK. P133 Evocative epidemiology of female breast cancer in Delhi, India. The Breast. 2015 Mar 1;24:S70–71.
8. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005 Dec;6(5):391–401.
9. Masters JR. Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol. 2000 Dec;1(3):233–236.
10. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006 Dec;10(6):515–527.
11. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017 May; 18(1):83.
12. Chen W-H, Lu G, Chen X, Zhao X-M, Bork P. OGEE v2: an update of the online gene essentiality database with special focus on differentially essential genes in human cancer cell lines. Nucleic Acids Res. 2017 Jan;45(D1): D940–944.
13. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002 Feb;62(4):1139–1147.
14. Mirabelli P, Coppola L, Salvatore M. Cancer cell lines are useful model systems for medical research. Cancers (Basel). 2019;11(8):1098.
15. Dai X, Cheng H, Bai Z, Li J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017;8(16):3131–3141.
16. Burdall SE, Hanby AM, Lansdown MRJ, Speirs V. Breast cancer cell lines: friend or foe? Breast Cancer Res. 2003;5(2):89–95.
17. Lee A V, Oesterreich S, Davidson NE. MCF-7 cells--changing the course of breast cancer research and care for 45 years. J Natl Cancer Inst. 2015 Jul;107(7).
18. Zheng X, Meng W-D, Xu Y-Y, Cao J-G, Qing F-L. Synthesis and anticancer effect of chrysin derivatives. Bioorg Med Chem Lett. 2003 Mar;13(5):881–884.
19. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002 Feb;94(4):252–266.
20. Lichtenberger LM, Vijayan KV. Are Platelets the Primary Target of Aspirin’s Remarkable Anticancer Activity? Cancer Res. 2019 Aug;79(15):3820–3823.
21. Jacob J, Tazawa M. Glucose–aspirin: Synthesis and in vitro anti-cancer activity studies. Bioorg Med Chem Lett. 2012 Mar 23;22:3168–3171.
22. Bashir AIJ, Kankipati CS, Jones S, Newman RM, Safrany ST, Perry CJ, et al. A novel mechanism for the anticancer activity of aspirin and salicylates. Int J Oncol. 2019 Apr;54(4):1256–1270.
23. gu M, Nishihara R, Chen Y, Wanwan L, Shi Y, Masugi Y, et al. Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget. 2017 Sep 18;8.
24. Zong M, Fan D-D, Lin S, Song Y-P, Wang Z-Y, Ma X-L, et al. Anti-cancer activity and potential mechanism of a novel aspirin derivative. Eur J Pharmacol. 2016 Nov;791:137–146.
25. Shen W, Zhang X, Du R, Gao W, Wang J, Bao Y, et al. Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner. Br J Cancer [Internet]. 2020;123(5):730–741. Available from: https://doi.org/10.1038/s41416-020-0906-7
26. Sakr A, Rezq S, Ibrahim SM, Soliman E, Baraka MM, Romero DG, et al. Design and synthesis of novel quinazolinones conjugated ibuprofen, indole acetamide, or thioacetohydrazide as selective COX-2 inhibitors: anti-inflammatory, analgesic and anticancer activities. J Enzyme Inhib Med Chem. 2021 Dec;36(1):1810–1828.
27. Yiannakopoulou EC. Aspirin and NSAIDs for breast cancer chemoprevention. Eur J cancer Prev Off J Eur Cancer Prev Organ. 2015 Sep;24(5):416–421.
28. Cheng R, Liu Y-J, Cui J-W, Yang M, Liu X-L, Li P, et al. Aspirin regulation of c- myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor- positive breast cancer cells. Oncotarget. 2017 May;8(18):30252–30264.
29. Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta- catenin/TCF-4 signaling. Biochem Pharmacol. 2009 Nov;78(10):1298–1304.
30. Pennock ND, Martinson HA, Guo Q, Betts CB, Jindal S, Tsujikawa T, et al. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother cancer. 2018 Oct;6(1):98.
31. Silva EF da, Santos PR dos, Fernandes KHA, Freitas D do N de, Zanin RF, Machado P, et al. Cytotoxic Effects of Diclofenac and Ibuprofen Zinc (II)-Nicotinamide Ternary Complexes in Breast Cancer Cell Lines. Brazilian Arch Biol Technol. 2021;64.
32. Moris D, Kontos M, Spartalis E, Fentiman IS. The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives. Breast Care (Basel). 2016 Oct;11(5):339–344.
33. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non- selective COX-2 blockade (review). Oncol Rep. 2005 Apr;13(4):559–583.
34. Bilani N, Bahmad H, Abou-Kheir W. Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms. Front Pharmacol. 2017;8:145.
35. Voutsadakis IA, Patrikidou A, Tsapakidis K, Karagiannaki A, Hatzidaki E, Stathakis NE, et al. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. Int J Colorectal Dis. 2010 Jul;25(7):795–804.
36. Abourehab MAS, Alqahtani AM, Almalki FA, Zaher DM, Abdalla AN, Gouda AM, et al. Pyrrolizine/Indolizine-NSAID Hybrids: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies. Molecules. 2021 Oct;26(21).
37. Weninger A, Baecker D, Obermoser V, Egger D, Wurst K, Gust R. Synthesis and Biological Evaluation of Zeise’s Salt Derivatives with Acetylsalicylic Acid Substructure. Int J Mol Sci. 2018 May;19(6).
38. Xu L, Xiao S, Yuan W, Cui J, Su G, Zhao Y. Synthesis and Anticancer Activity Evaluation of Hydrolyzed Derivatives of Panaxnotoginseng Saponins. Molecules. 2018 Nov;23(11).
39. Hu L-X, Du Y-Y, Zhang Y, Pan Y-Y. Synergistic effects of exemestane and
aspirin on MCF-7 human breast cancer cells. Asian Pac J Cancer Prev. 2012;13(11):5903–5908.
40. Bardaweel SK, Dahabiyeh LA, Akileh BM, Shalabi DD, AlHiary AK, Pawling J,
et al. Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy against Breast Cancer Cell Models. Anti-Cancer Agents. Med Chem (Formerly Curr Med Chem Agents). 2022;22(8):1611–1621.
41. Bülbül B, Ding K, Zhan C-G, Çiftçi G, Yelekçi K, Gürboğa M, et al. Novel 1,2,4- triazoles derived from Ibuprofen: synthesis and in vitro evaluation of their mPGES-1 inhibitory and antiproliferative activity. 2022; Available from: https://doi.org/10.1007/s11030-022-10551-0